TMCnet News

Research and Markets: NASH Is Currently The Third Most Common Factor Leading to Liver Transplants in the US, 2015 Report Says
[September 23, 2015]

Research and Markets: NASH Is Currently The Third Most Common Factor Leading to Liver Transplants in the US, 2015 Report Says


Research and Markets (http://www.researchandmarkets.com/research/7x6ssw/nash_drugs) has announced the addition of the "NASH Drugs Market, 2015 - 2025" report to their offering.

The 'NASH Drugs Market, 2015-2025' report provides a comprehensive study on the current landscape and the future outlook of the evolving pipeline of molecules in this area. With an expanding NAFLD and NASH population worldwide, there is a growing need for development of therapeutics in this disease area.

NASH is gradually emerging as the leading cause of liver transplants. While the field has garnered interest of several companies, there are no approved therapies to date. It is important to stress that the development pipeline of NASH has several promising candidates that are likely to result in many commercial success stories in the foreseen future.

Amongst other elements, the report elaborates on the new diagnostic solutions being developed and the upcoming opportunities for different stakeholders. As pharmaceutical companies continue to initiate and expand their research programs in this area,one of the key objectives outlined for this report is to understand the future potential of the market. This is done by analyzing:



  • The epidemiology, patient population and staging of NASH in different geographies.
  • The NASH pipeline in terms of phase of development, type of molecule, route of administration and mechanism of action.
  • The likely evolution in the rate of diagnosis, drug treated patient population and the likely price of the drugs.
  • The associated constraints, in terms of undefined pathogenesis and the unavailability of non-invasive diagnostic tests, and the initiatives being carried out by the companies to overcome these.

Key Topics Covered

  1. Preface
  2. Executive Summary
  3. Introduction
  4. Treatment Options And Diagnostic Solutions
  5. Market Dynamics
  6. Market Overview
  7. Upcoming Nash Drugs: Detailed Profiles
  8. Market Sizing And Opportunity Analysis
  9. Company Profiles
  10. Conclusion
  11. Interview Transcripts
  12. Appendix

Companies Mentioned


Partial list of the 70+ companies featured in this comprehensive report:

  • Alnylam Pharmaceuticals
  • BiOrion Technologies
  • Cadila Healthcare
  • DS Biopharma
  • Encode Pharmaceuticals
  • Fournier
  • Galectin Therapeutics
  • Idun
  • Johns Hopkins University
  • Kadmon
  • LibbsFarmaceutica
  • Madrigal Pharmaceuticals
  • Naia Pharmaceuticals
  • One Way Liver Genomics
  • Perrigo API
  • Raptor Pharmaceuticals
  • Sanofi-Aventis
  • Taiwan Pharmaceuticals
  • Verlyx Pharma
  • XTuit Pharmaceuticals
  • Zafgen

Full list available at http://www.researchandmarkets.com/research/7x6ssw/nash_drugs


[ Back To TMCnet.com's Homepage ]